Association of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).
Goswamy R, Yildirim A, Wei M, Liu Y, Choi Y, Brown J, Nazha B, Master V, Martini D, Carthon B, Harris W, Kucuk O, Kissick H, Hartman C, McClintock G, Vo B, Jansen C, Zhuang T, Bilen M. Association of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2024, 42: e16527-e16527. DOI: 10.1200/jco.2024.42.16_suppl.e16527.Peer-Reviewed Original ResearchCD8 T cell infiltrationMetastatic renal cell carcinomaProgression-free survivalT cell infiltrationCD8 T cellsCheckpoint inhibitorsOverall survivalTyrosine kinase inhibitorsT cellsSystemic therapyTumor microenvironmentMetastatic renal cell carcinoma patientsAssociated with favorable clinical outcomesProgression-free survival outcomesRetrospective analysis of patientsCombination checkpoint inhibitorsIntratumoral T cellsProgression free survivalImproved overall survivalFavorable clinical outcomesWinship Cancer InstituteKaplan Meier analysisAnalysis of patientsRenal cell carcinomaCox proportional hazards modelsImpact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
Patel J, Woo Y, Draper A, Jansen C, Carlisle J, Innominato P, Lévi F, Dhabaan L, Master V, Bilen M, Khan M, Lowe M, Kissick H, Buchwald Z, Qian D. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. Journal For ImmunoTherapy Of Cancer 2024, 12: e008011. PMID: 38531662, PMCID: PMC10966813, DOI: 10.1136/jitc-2023-008011.Peer-Reviewed Original ResearchConceptsInfusions of immune checkpoint inhibitorsMetastatic renal cell carcinomaProgression-free survivalOverall survivalRenal cell carcinomaCell carcinomaInternational Metastatic RCC Database Consortium risk scoreAssociated with longer progression-free survivalLung cancerGroup BGroup ATime of ICI initiationLonger progression-free survivalNon-small cell lung cancerMultivariable Cox proportional hazards regressionImmune checkpoint inhibitorsPretreatment lactate dehydrogenaseCell lung cancerCox proportional hazards regressionAdaptive immune responsesProportional hazards regressionMulticenter cohort analysisCheckpoint inhibitorsICI initiationMetastatic melanoma